We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back to AstraZeneca, terminating an agreement between the two firms that was struck in 2016.